AstraZeneca's Breztri Improves Lung Function in Uncontrolled Asthma Patients
AstraZeneca's Breztri Aerosphere has demonstrated statistically significant and clinically meaningful improvements in lung function for patients with uncontrolled asthma compared to dual-combination therapies, according to new trial results.
Full results from the Phase III KALOS and LOGOS trials, published in The Lancet Respiratory Medicine, indicate that AstraZeneca's Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) significantly improved lung function in patients with uncontrolled asthma when compared to dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines.
The trials showed Breztri improved forced expiratory volume in 1 second (FEV1) and demonstrated clinically meaningful reductions in the annualised rate of severe asthma exacerbations. This is a notable development as many of the 262 million people globally living with asthma still struggle with symptoms like breathlessness and coughing despite current treatments.
Clinicians are optimistic about Breztri's potential. Professor Alberto Papi highlighted that the triple-combination therapy improves lung function and prevents future severe exacerbations, regardless of a patient's prior history of exacerbations.
AstraZeneca is advancing regulatory filings for Breztri in asthma and expects its potential to improve lung function and prevent exacerbations will benefit patients. The therapy is already approved for chronic obstructive pulmonary disease (COPD) in over 80 countries worldwide.